Development of human natural killer cells and other innate lymphoid cells

Seminars in Immunology

Volumn 26, Issue 2, 2014, Pages 107-113

  Montaldo, Elisa ^a   Vacca, Paola ^a   Moretta, Lorenzo ^b   Mingari, Maria Cristina ^a,c  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

ILC development; ILC2; ILC3; NCR; NK cells

Indexed keywords

CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL POPULATION; CELLULAR DISTRIBUTION; HUMAN; INNATE IMMUNITY; INNATE LYMPHOID CELL 1; INNATE LYMPHOID CELL2; INNATE LYMPHOID CELL3; LYMPHOID CELL; NATURAL KILLER CELL; NONHUMAN; REVIEW; ANIMAL; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS;

EID: 84897958129     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.01.006     Document Type: Review

References (130)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376.
2. Spits H., Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012, 30:647-675.
3. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
4. Walker J.A., Barlow J.L., McKenzie A.N. Innate lymphoid cells - how did we miss them?. Nat Rev Immunol 2013, 13:75-87.
5. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
6. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
7. Walker J.A., McKenzie A.N. Development and function of group 2 innate lymphoid cells. Curr Opin Immunol 2013, 25:148-155.
8. Erlebacher A. Immunology of the maternal-fetal interface. Annu Rev Immunol 2013, 31:387-411.
9. Cherrier M., Ohnmacht C., Cording S., Eberl G. Development and function of intestinal innate lymphoid cells. Curr Opin Immunol 2012, 24:277-283.
10. Fuchs A., Vermi W., Lee J.S., Lonardi S., Gilfillan S., Newberry R.D., et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 2013, 38:769-781.
11. Bernink J.H., Peters C.P., Munneke M., te Velde A.A., Meijer S.L., Weijer K., et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013, 14:221-229.
12. Herberman R.B., Nunn M.E., Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975, 16:216-229.
13. Herberman R.B., Nunn M.E., Holden H.T., Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975, 16:230-239.
14. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975, 5:112-117.
15. Kiessling R., Klein E., Pross H., Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975, 5:117-121.
16. Sivori S., Falco M., Della Chiesa M., Carlomagno S., Vitale M., Moretta L., et al. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci USA 2004, 101:10116-10121.
17. Marcenaro E., Ferranti B., Falco M., Moretta L., Moretta A. Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. Int Immunol 2008, 20:1155-1167.
18. Moretta A., Bottino C., Vitale M., Pende D., Biassoni R., Mingari M.C., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996, 14:619-648.
19. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223.
20. Cantoni C., Bottino C., Vitale M., Pessino A., Augugliaro R., Malaspina A., et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999, 189:787-796.
21. Pende D., Parolini S., Pessino A., Sivori S., Augugliaro R., Morelli L., et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999, 190:1505-1516.
22. Sivori S., Vitale M., Morelli L., Sanseverino L., Augugliaro R., Bottino C., et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997, 186:1129-1136.
23. Vitale M., Bottino C., Sivori S., Sanseverino L., Castriconi R., Marcenaro E., et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998, 187:2065-2072.
24. Moretta A., Vitale M., Bottino C., Orengo A.M., Morelli L., Augugliaro R., et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993, 178:597-604.
25. Kruse P.H., Matta J., Ugolini S., Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol 2013, 10.1038/icb.2013.98.
26. Pogge von Strandmann E., Simhadri V.R., von Tresckow B., Sasse S., Reiners K.S., Hansen H.P., et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007, 27:965-974.
27. Brandt C.S., Baratin M., Yi E.C., Kennedy J., Gao Z., Fox B., et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009, 206:1495-1503.
28. Baychelier F., Sennepin A., Ermonval M., Dorgham K., Debre P., Vieillard V. Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood 2013, 122:2935-2942.
29. Mandelboim O., Lieberman N., Lev M., Paul L., Arnon T.I., Bushkin Y., et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001, 409:1055-1060.
30. Arnon T.I., Lev M., Katz G., Chernobrov Y., Porgador A., Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001, 31:2680-2689.
31. Bottino C., Castriconi R., Pende D., Rivera P., Nanni M., Carnemolla B., et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003, 198:557-567.
32. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-502.
33. Bottino C., Falco M., Parolini S., Marcenaro E., Augugliaro R., Sivori S., et al. NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 2001, 194:235-246.
34. Vitale M., Falco M., Castriconi R., Parolini S., Zambello R., Semenzato G., et al. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol 2001, 31:233-242.
35. Moretta A., Bottino C., Tripodi G., Vitale M., Pende D., Morelli L., et al. Novel surface molecules involved in human NK cell activation and triggering of the lytic machinery. Int J Cancer Suppl 1992, 7:6-10.
36. Lanier L.L., Le A.M., Phillips J.H., Warner N.L., Babcock G.F. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 1983, 131:1789-1796.
37. Perussia B., Acuto O., Terhorst C., Faust J., Lazarus R., Fanning V., et al. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J Immunol 1983, 130:2142-2148.
38. Perussia B., Starr S., Abraham S., Fanning V., Trinchieri G. Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1. J Immunol 1983, 130:2133-2141.
39. Welte S., Kuttruff S., Waldhauer I., Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 2006, 7:1334-1342.
40. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
41. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006, 214:73-91.
42. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006, 107:159-166.
43. De Maria A., Bozzano F., Cantoni C., Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci USA 2011, 108:728-732.
44. Fauriat C., Long E.O., Ljunggren H.G., Bryceson Y.T. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010, 115:2167-2176.
45. Ferlazzo G., Thomas D., Lin S.L., Goodman K., Morandi B., Muller W.A., et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004, 172:1455-1462.
46. Romagnani C., Juelke K., Falco M., Morandi B., D'Agostino A., Costa R., et al. CD56brightCD16-killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 2007, 178:4947-4955.
47. Moretta A. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2002, 2:957-964.
48. Carrega P., Ferlazzo G. Natural killer cell distribution and trafficking in human tissues. Front Immunol 2012, 3:347.
49. Vacca P., Moretta L., Moretta A., Mingari M.C. Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol 2011, 32:517-523.
50. Stojanovic A., Correia M.P., Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron 2013, 6:135-146.
51. Marcenaro E., Della Chiesa M., Bellora F., Parolini S., Millo R., Moretta L., et al. IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 2005, 174:3992-3998.
52. Moretta L., Ferlazzo G., Bottino C., Vitale M., Pende D., Mingari M.C., et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev 2006, 214:219-228.
53. Vacca P., Mingari M.C., Moretta L. Natural killer cells in human pregnancy. J Reprod Immunol 2013, 97:14-19.
54. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002, 2:656-663.
55. Vacca P., Cantoni C., Prato C., Fulcheri E., Moretta A., Moretta L., et al. Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. Int Immunol 2008, 20:1395-1405.
56. Vacca P., Cantoni C., Vitale M., Prato C., Canegallo F., Fenoglio D., et al. Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc Natl Acad Sci USA 2010, 107:11918-11923.
57. Balsamo M., Pietra G., Vermi W., Moretta L., Mingari M.C., Vitale M. Melanoma immunoediting by NK cells. Oncoimmunology 2012, 1:1607-1609.
58. Pietra G., Manzini C., Rivara S., Vitale M., Cantoni C., Petretto A., et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012, 72:1407-1415.
59. Mamessier E., Sylvain A., Thibult M.L., Houvenaeghel G., Jacquemier J., Castellano R., et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011, 121:3609-3622.
60. Vacca P., Martini S., Mingari M.C., Moretta L. NK cells from malignant pleural effusions are potent antitumor effectors: a clue for adoptive immunotherapy?. Oncoimmunology 2013, 2:e23638.
61. Montaldo E., Del Zotto G., Della Chiesa M., Mingari M.C., Moretta A., De Maria A., et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 2013, 83:702-713.
62. Yu J., Freud A.G., Caligiuri M.A. Location and cellular stages of natural killer cell development. Trends Immunol 2013, 34:573-582.
63. Yokota Y., Mansouri A., Mori S., Sugawara S., Adachi S., Nishikawa S., et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999, 397:702-706.
64. Boos M.D., Yokota Y., Eberl G., Kee B.L. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med 2007, 204:1119-1130.
65. Colucci F., Samson S.I., DeKoter R.P., Lantz O., Singh H., Di Santo J.P. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 2001, 97:2625-2632.
66. Barton K., Muthusamy N., Fischer C., Ting C.N., Walunas T.L., Lanier L.L., et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998, 9:555-563.
67. Aliahmad P., de la Torre B., Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol 2010, 11:945-952.
68. Yun S., Lee S.H., Yoon S.R., Kim M.S., Piao Z.H., Myung P.K., et al. TOX regulates the differentiation of human natural killer cells from hematopoietic stem cells in vitro. Immunol Lett 2011, 136:29-36.
69. Gascoyne D.M., Long E., Veiga-Fernandes H., de Boer J., Williams O., Seddon B., et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 2009, 10:1118-1124.
70. Kamizono S., Duncan G.S., Seidel M.G., Morimoto A., Hamada K., Grosveld G., et al. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med 2009, 206:2977-2986.
71. Gordon S.M., Chaix J., Rupp L.J., Wu J., Madera S., Sun J.C., et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012, 36:55-67.
72. Freud A.G., Caligiuri M.A. Human natural killer cell development. Immunol Rev 2006, 214:56-72.
73. Minagawa M., Watanabe H., Miyaji C., Tomiyama K., Shimura H., Ito A., et al. Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor beta-chain-deficient mice. J Immunol 2002, 169:4153-4160.
74. Yu H., Fehniger T.A., Fuchshuber P., Thiel K.S., Vivier E., Carson W.E., et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 1998, 92:3647-3657.
75. Carson W.E., Haldar S., Baiocchi R.A., Croce C.M., Caligiuri M.A. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci USA 1994, 91:7553-7557.
76. Sivori S., Cantoni C., Parolini S., Marcenaro E., Conte R., Moretta L., et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 2003, 33:3439-3447.
77. Hughes T., Becknell B., Freud A.G., McClory S., Briercheck E., Yu J., et al. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity 2010, 32:803-814.
78. Montaldo E., Vitale C., Cottalasso F., Conte R., Glatzer T., Ambrosini P., et al. Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor. Blood 2012, 119:3987-3996.
79. Blom B., Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006, 24:287-320.
80. Freud A.G., Yokohama A., Becknell B., Lee M.T., Mao H.C., Ferketich A.K., et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006, 203:1033-1043.
81. Ahn Y.O., Blazar B.R., Miller J.S., Verneris M.R. Lineage relationships of human interleukin-22-producing CD56+ RORgammat+ innate lymphoid cells and conventional natural killer cells. Blood 2013, 121:2234-2243.
82. Vacca P., Vitale C., Montaldo E., Conte R., Cantoni C., Fulcheri E., et al. CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci USA 2011, 108:2402-2407.
83. Loza M.J., Perussia B. Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation?. Nat Immunol 2001, 2:917-924.
84. Rosmaraki E.E., Douagi I., Roth C., Colucci F., Cumano A., Di Santo J.P. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol 2001, 31:1900-1909.
85. Di Santo J.P. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006, 24:257-286.
86. Moroso V., Famili F., Papazian N., Cupedo T., van der Laan L.J., Kazemier G., et al. NK cells can generate from precursors in the adult human liver. Eur J Immunol 2011, 41:3340-3350.
87. Mingari M.C., Poggi A., Biassoni R., Bellomo R., Ciccone E., Pella N., et al. In vitro proliferation and cloning of CD3- CD16+ cells from human thymocyte precursors. J Exp Med 1991, 174:21-26.
88. Freud A.G., Becknell B., Roychowdhury S., Mao H.C., Ferketich A.K., Nuovo G.J., et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005, 22:295-304.
89. Chinen H., Matsuoka K., Sato T., Kamada N., Okamoto S., Hisamatsu T., et al. Lamina propria c-kit+ immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007, 133:559-573.
90. Male V., Hughes T., McClory S., Colucci F., Caligiuri M.A., Moffett A. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol 2010, 185:3913-3918.
91. Poggi A., Sargiacomo M., Biassoni R., Pella N., Sivori S., Revello V., et al. Extrathymic differentiation of T lymphocytes and natural killer cells from human embryonic liver precursors. Proc Natl Acad Sci USA 1993, 90:4465-4469.
92. Mebius R.E., Miyamoto T., Christensen J., Domen J., Cupedo T., Weissman I.L., et al. The fetal liver counterpart of adult common lymphoid progenitors gives rise to all lymphoid lineages, CD45+CD4+CD3- cells, as well as macrophages. J Immunol 2001, 166:6593-6601.
93. Vargas C.L., Poursine-Laurent J., Yang L., Yokoyama W.M. Development of thymic NK cells from double negative 1 thymocyte precursors. Blood 2011, 118:3570-3578.
94. Vosshenrich C.A., Garcia-Ojeda M.E., Samson-Villeger S.I., Pasqualetto V., Enault L., Richard-Le Goff O., et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 2006, 7:1217-1224.
95. Le Bouteiller P., Tabiasco J. Killers become builders during pregnancy. Nat Med 2006, 12:991-992.
96. Chiossone L., Vacca P., Orecchia P., Croxatto D., Damonte P., Astigiano S., et al. In vivo generation of decidual Natural Killer cells from resident hematopoietic progenitors. Haematologica 2013, [Epub ahead of print].
97. Della Chiesa M., Falco M., Podesta M., Locatelli F., Moretta L., Frassoni F., et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood. 2012, 119:399-410.
98. Eberl G., Marmon S., Sunshine M.J., Rennert P.D., Choi Y., Littman D.R. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol 2004, 5:64-73.
99. Luci C., Reynders A., Ivanov I.I., Cognet C., Chiche L., Chasson L., et al. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol 2009, 10:75-82.
100. Sanos S.L., Bui V.L., Mortha A., Oberle K., Heners C., Johner C., et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol 2009, 10:83-91.
101. Satoh-Takayama N., Vosshenrich C.A., Lesjean-Pottier S., Sawa S., Lochner M., Rattis F., et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 2008, 29:958-970.
102. Vonarbourg C., Diefenbach A. Multifaceted roles of interleukin-7 signaling for the development and function of innate lymphoid cells. Semin Immunol 2012, 24:165-174.
103. Chappaz S., Gartner C., Rodewald H.R., Finke D. Kit ligand and Il7 differentially regulate Peyer's patch and lymph node development. J Immunol 2010, 185:3514-3519.
104. Kiss E.A., Vonarbourg C., Kopfmann S., Hobeika E., Finke D., Esser C., et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science 2011, 334:1561-1565.
105. Lee J.S., Cella M., McDonald K.G., Garlanda C., Kennedy G.D., Nukaya M., et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 2012, 13:144-151.
106. Qiu J., Heller J.J., Guo X., Chen Z.M., Fish K., Fu Y.X., et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 2012, 36:92-104.
107. Kelly K.A., Scollay R. Seeding of neonatal lymph nodes by T cells and identification of a novel population of CD3-CD4+ cells. Eur J Immunol 1992, 22:329-334.
108. Mebius R.E., Rennert P., Weissman I.L. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 1997, 7:493-504.
109. Randall T.D., Carragher D.M., Rangel-Moreno J. Development of secondary lymphoid organs. Annu Rev Immunol 2008, 26:627-650.
110. van de Pavert S.A., Mebius R.E. New insights into the development of lymphoid tissues. Nat Rev Immunol 2010, 10:664-674.
111. Cupedo T., Crellin N.K., Papazian N., Rombouts E.J., Weijer K., Grogan J.L., et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127(+) natural killer-like cells. Nat Immunol 2009, 10:66-74.
112. Takatori H., Kanno Y., Watford W.T., Tato C.M., Weiss G., Ivanov I.I., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009, 206:35-41.
113. Cella M., Fuchs A., Vermi W., Facchetti F., Otero K., Lennerz J.K., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
114. Crellin N.K., Trifari S., Kaplan C.D., Cupedo T., Spits H. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010, 207:281-290.
115. Spits H., Di Santo J.P. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011, 12:21-27.
116. Glatzer T., Killig M., Meisig J., Ommert I., Luetke-Eversloh M., Babic M., et al. RORgammat(+) innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity 2013, 38:1223-1235.
117. Crellin N.K., Trifari S., Kaplan C.D., Satoh-Takayama N., Di Santo J.P., Spits H. Regulation of cytokine secretion in human CD127(+) LTi-like innate lymphoid cells by Toll-like receptor 2. Immunity 2010, 33:752-764.
118. Hanash A.M., Dudakov J.A., Hua G., O'Connor M.H., Young L.F., Singer N.V., et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012, 37:339-350.
119. Sawa S., Cherrier M., Lochner M., Satoh-Takayama N., Fehling H.J., Langa F., et al. Lineage relationship analysis of RORgammat+ innate lymphoid cells. Science 2010, 330:665-669.
120. Vonarbourg C., Mortha A., Bui V.L., Hernandez P.P., Kiss E.A., Hoyler T., et al. Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 2010, 33:736-751.
121. Moro K., Yamada T., Tanabe M., Takeuchi T., Ikawa T., Kawamoto H., et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010, 463:540-544.
122. Neill D.R., Wong S.H., Bellosi A., Flynn R.J., Daly M., Langford T.K., et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464:1367-1370.
123. Price A.E., Liang H.E., Sullivan B.M., Reinhardt R.L., Eisley C.J., Erle D.J., et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 2010, 107:11489-11494.
124. Wong S.H., Walker J.A., Jolin H.E., Drynan L.F., Hams E., Camelo A., et al. Transcription factor RORalpha is critical for nuocyte development. Nat Immunol 2012, 13:229-236.
125. Halim T.Y., MacLaren A., Romanish M.T., Gold M.J., McNagny K.M., Takei F. Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. Immunity 2012, 37:463-474.
126. Hoyler T., Klose C.S., Souabni A., Turqueti-Neves A., Pfeifer D., Rawlins E.L., et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 2012, 37:634-648.
127. Mjosberg J., Bernink J., Golebski K., Karrich J.J., Peters C.P., Blom B., et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012, 37:649-659.
128. Mjosberg J.M., Trifari S., Crellin N.K., Peters C.P., van Drunen C.M., Piet B., et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011, 12:1055-1062.
129. Loza M.J., Zamai L., Azzoni L., Rosati E., Perussia B. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 2002, 99:1273-1281.
130. Locatelli F., Pende D., Mingari M.C., Bertaina A., Falco M., Moretta A., et al. Cellular and molecular basis of haploidentical hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol 2013, 4:15.